Abstract
Pemphigus is a group of autoimmune bullous disorders with different types. Pemphigus foliaceous (PF) is a difficult‐to‐diagnosis disorder which shares clinical features with many dermatoses. We hereby, present an interesting case of PF which serves as a reminder for clinicians that pemphigus is not always a serious condition with rapid extension of lesions and it could have a very limited and benign form.
This case report showed that pemphigus is not always a serious condition with rapid extension of lesions and it could have a very limited and benign form.
1. CASE PRESENTATION
A 32‐year‐old male presented to the dermatologic clinic with two asymptomatic facial lesions without any change in size over the course of the past 12 months (Figure 1). The patient did not have any other skin eruptions, mucosal involvement or photosensitivity and any remarkable past medical history as well as occupational or family history.
FIGURE 1.
Two small erythematous macules on the right cheek (a) and forehead (b) area
Physical examination revealed two erythematous macules with approximate diameter of 5 mm on the forehead and beard area. We considered all of the differential diagnoses for facial annular erythematous lesions including discoid lupus erythematosus (DLE), sarcoidosis, granuloma annularis and seborrhoeic dermatitis. The histopathologic examination and direct immunofluorescence (DIF) assay were performed.
Skin biopsy from cheek lesion revealed Prominent changes within the superficial epidermis and acanthloysis was seen mainly within the stratum granulosum.
In the dermis, there was a predominantly superficial lymphocytic infiltrate with scattered scarce eosinophils (Figure 2). DIF study showed an intercellular deposit of IgG and C3 at the epidermis.
FIGURE 2.
Subcorneal cleavage and acantholysis
2. DISCUSSION
Pemphigus is a group of autoimmune bullous disorders with different types including pemphigus vulgaris (PV), Pemphigus foliaceous (PF), Paraneoplastic pemphigus, IgA pemphigus and Drug‐induced pemphigus. 1 , 2 Pemphigus foliaceous is the second most common pemphigus behind pemphigus vulgaris, which occurs as a result of anti‐desmoglein‐1 antibodies production against the intercellular adhesion DSG1 protein leading to acantholysis in the stratum granulosum and characterized by skin involvement, primarily at seborrhoeic areas, without any mucosal lesions. 3 Pemphigus foliaceus is classically presented with fragile loose blisters over seborrhoeic areas such as face, scalp and upper trunk. 4 There are several triggering factors for the evolution of pemphigus which include medications, vaccines, genetic predisposition, pregnancy and stress. 4
As mentioned before, PF is classically presented with fragile loose blisters over seborrhoeic areas such as face, scalp and upper trunk. The differentiating clinical characteristic of PF from pemphigus vulgaris (PV) is the mucous membrane sparing and extensive erythema in the former. 4 However, demonstrating separation of keratinocytes at the granular layer of the epidermis, pre‐acantholytic vacuole formation in intercellular spaces and subcorneal blisters in the histopathologic examination confirms the diagnosis of PF. 5 Direct immunofluorescence (DIF), demonstrating intercellular deposition of IgG and C3, and indirect immunofluorescence microscopy for detecting serum autoantibodies against DSGs are highly sensitive and specific methods for diagnosing pemphigus, as aided us significantly for the patient. 6
This case presented with two small, hard to notice, asymptomatic macules. Hence, diagnosing PF could be challenging due to its non‐specific clinical presentation which might lead to a delay in correct diagnosis. Differential diagnosis of facial macules and plaques is usually made with lichen planus, DLE, pseudolymphoma, sarcoidosis and annular granuloma which were either considered for our case. However, histopathologic assessment surprisingly revealed some characteristic features of PF.
Systemic corticosteroids are still the mainstay and first‐line treatment of pemphigus. However, in moderate‐to‐severe cases, oral azathioprine or a mycophenolate compound is added. 7 Based on the benign and limited course of disease in our patient, a topical corticosteroid was initiated for him, which led to complete resolution of skin lesions in 2 months.
This interesting case report high bolds the fact that PF might mimic various more common dermatoses, in particular when it appears as a few small lesions with a benign manner.
The serologic assay in this case regarding both anti Dsg‐1 and anti Dsg‐3 was negative which explains the benign course of disorder without developing any new lesion over last 12 months.
Because of facial involvement in this case, Senear‐Usher syndrome also known as pemphigus erythematosus, was also considered which is an overlap syndrome with features of lupus erythematosus (LE) and pemphigus foliaceus. However, histological and DIF evaluations were not consistent with this diagnosis.
This case report showed that pemphigus is not always a serious condition with rapid extension of lesions and it could have a very limited and benign form. However, owing to unpredictable course of autoimmune disorders and few case reports of patients with an established diagnosis of PF developing pemphigus vulgaris later in the course of their disease, 8 , 9 , 10 long‐term follow up of this patient and those with similar features is strongly recommended.
In conclusion, PF is a difficult‐to‐diagnosis disorder which shares clinical features with many dermatoses. Clinical suspicion is necessary to ensure correct diagnosis and start the appropriate treatment.
CONFLICTS OF INTEREST
The authors declare that they have no conflict of interest regarding the publication of this article.
AUTHOR CONTRIBUTIONS
Kamran Balighi: Conceptualization; Equal, Supervision; Equal, Kambiz Kamyab‐hesari: Investigation; Equal, Methodology; Equal, Zeynab Aryaniyan: Data curation; Equal, Writing – original draft; Equal, Parvaneh Hatami: Investigation; Equal, Writing – review & editing; Equal.
ETHICS STATEMENT
The patients provided written informed contest to publication of this case report and accompanying images.
ACKNOWLEDGEMENTS
The authors would like to thank Razi Hospital Clinical Research Development Center and Autoimmune Bullous Diseases Research Center for their technical and editorial assistance.
Balighi K, Kamyab‐hesari K, Hatami P, Aryanian Z. Two asymptomatic facial erythematous macules in an adult male. Skin Health Dis. 2023;3(1):e172. 10.1002/ski2.172
Contributor Information
Parvaneh Hatami, Email: p_hatami2001@yahoo.com.
Zeinab Aryanian, Email: aryanian@sina.tums.ac.ir.
DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author, upon reasonable request.
REFERENCES
- 1. Mohammad‐Javad N, Parvaneh H, Maryam G, Maryam D, Cheyda C. Randomized trial of tacrolimus 0.1% ointment versus triamcinolone acetonide 0.1% paste in the treatment of oral pemphigus vulgaris. Iran J Dermatol. 2012;15(2):42–6. [Google Scholar]
- 2. Aryanian Z, Balighi K, Daneshpazhooh M, Karamshahi E, Hatami P, Goodarzi A, et al. Vance, Rituximab exhibits a better safety profile when used as a first line of treatment for pemphigus vulgaris: a retrospective study. Int Immunopharm. 2021;96:107755. 10.1016/j.intimp.2021.107755 [DOI] [PubMed] [Google Scholar]
- 3. Lepe K, Yarrarapu SNS, Zito PM. Pemphigus foliaceus. In: StatPearls [Internet]. Treasure Island (FL). StatPearls Publishing; 2021. [PubMed] [Google Scholar]
- 4. Hans‐Filho G, Aoki V, Bittner NRH, Bittner GC. Fogo selvagem: endemic pemphigus foliaceus. An Bras Dermatol. 2018;93(5):638–50. 10.1590/abd1806-4841.20188235 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Balighi K, Hatami P, Sheikh Aboli MJ, Daneshpazhooh M, Ghiasi M, Mahmoudi HR, et al. Multiple cycles of rituximab therapy for pemphigus: a group of patients with difficult‐ to‐treat disease or a consequence of late rituximab initiation? Dermatol Ther. 2022. Apr 13;35(2):e15249. Epub ahead of print. 10.1111/dth.15249 [DOI] [PubMed] [Google Scholar]
- 6. Hatami P, Balighi K, Mohandesi NA, Asl HN, Aryanian Z. Dexamethasone or Prednisone: which one should be the corticosteroid of choice in patients with pemphigus vulgaris? Dermatol Ther. 2022;35(7):e15511. Epub ahead of print. 10.1111/dth.15511 [DOI] [PubMed] [Google Scholar]
- 7. Mohaghegh F, Hatami P, Refaghat A, Mehdizadeh M, Aryanian Z, Mohandesi NA, et al. New‐onset pemphigus foliaceus following SARS‐CoV‐2 infection and unmasking multiple sclerosis: a case report. Clin Case Rep. 2022;10(6):e05910. 10.1002/ccr3.5910 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Komai A, Amagai M, Ishii K, Nishikawa T, Chorzelski T, Matsuo I, et al. The clinical transition between pemphigus foliaceus and pemphigus vulgaris correlates well with the changes in autoantibody profile assessed by an enzyme‐linked immunosorbent assay. Br J Dermatol. 2001;144(6):1177–82. 10.1046/j.1365-2133.2001.04227.x [DOI] [PubMed] [Google Scholar]
- 9. Park SG, Chang JY, Cho Y‐H, Kim S‐C, Lee M‐G. Transition from pemphigus foliaceus to pemphigus vulgaris: case report with literature review. Yonsei Med J. 2006;47(2):278–81. 10.3349/ymj.2006.47.2.278 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10. Ishii K, Amagai M, Ohata Y, Shimizu H, Hashimoto T, Ohya K, et al. Development of pemphigus vulgaris in a patient with pemphigus foliaceus: antidesmoglein antibody profile shift confirmed by enzyme‐linked immunosorbent assay. J Am Acad Dermatol. 2000;42(5 Pt 2):859–61. 10.1016/s0190-9622(00)90253-6 [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
The data that support the findings of this study are available from the corresponding author, upon reasonable request.